Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
237
-
Total 13F shares, excl. options
-
53.6M
-
Shares change
-
-880K
-
Total reported value, excl. options
-
$3.11B
-
Value change
-
-$26.1M
-
Put/Call ratio
-
1.57
-
Number of buys
-
116
-
Number of sells
-
-103
-
Price
-
$58.08
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q4 2017
259 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q4 2017.
HAEMONETICS CORP - Common Stock (HAE) has 237 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.6M shares
.
Largest 10 shareholders include BlackRock Inc. (6.67M shares), Vanguard Group Inc (5.02M shares), WELLINGTON MANAGEMENT GROUP LLP (3.79M shares), VICTORY CAPITAL MANAGEMENT INC (2.43M shares), WELLS FARGO & COMPANY/MN (2.12M shares), Neuberger Berman Group LLC (1.95M shares), DIMENSIONAL FUND ADVISORS LP (1.6M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.52M shares), HealthCor Management, L.P. (1.45M shares), and STATE STREET CORP (1.4M shares).
This table shows the top 237 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.